These medications topped the list of money-makers last year. [© grandeduc - Fotolia.com]
#10. Cymbalta (duloxetine)
Drug maker: Eli Lilly
Indication(s): Major depressive disorder, generalized anxiety disorder, management of diabetic peripheral neuropathic pain and fibromyalgia; management of chronic musculoskeletal pain due to chronic osteoarthritis pain and chronic low back pain
2012 sales: $4.994 billion
2011 sales: $4.161 billion
% change: 20.0%
Q4 2012 sales: $1.420 billion, up 20.3% from $1.181 billion in Q4 2011
#9. Avastin (bevacizumab)
Drug maker: Roche
Indication(s): Metastatic colorectal cancer (colon cancer), non–small cell lung cancer, glioblastoma & metastatic kidney
2012 sales: $6.260 billion (CHF 5.764 billion)3
2011 sales: $5.747 billion (CHF 5.292 billion)3
% Change: 6% at CER
Q4 2012 sales: $1.580 billion (CHF 1.455 billion), up 7.8% from $1.466 billion (CHF 1.350 billion) in Q4 20113
#8. Crestor (rosuvastatin calcium)
Drug maker: AstraZeneca
Indication(s): Reduction of Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides in the blood, as an adjunct to diet
2012 sales: $6.253 billion
2011 sales: $6.622 billion
% Change: -4% at CER
Q4 2012 sales: $1.622 billion, down 7% at CER from $1.771 billion in Q4 2011
#7. Herceptin (trastuzumab)
Drug maker: Roche
Indication(s): HER2-positive breast cancer and HER2-positive metastatic gastric cancer
2012 sales: $6.397 billion (CHF 5.889 billion)4
2011 sales: $5.706 billion (CHF 5.253 billion)4
% Change: 11% at CER
Q4 2012 sales: $1.583 billion (CHF 1.457 billion), up 8.1% from $1.464 billion (CHF 1.348 billion) in Q4 20114
#6. Lantus (insulin glargine)
Drug maker: Sanofi
Indication(s): Once daily treatment for diabetes
2012 sales: $6.648 billion (€4.960 billion)5
2011 sales: $5.249 billion (€3.916 billion)5
% Change: 19.3% at CER
Q4 2012 sales: $1.789 billion (€1.335 billion), up 22.6% at CER from $1.413 billion (€1.054 billion) in 4Q 2011 at CER5
#5. Rituxan (rituximab, MabThera)
Drug maker: Roche
Indication(s): Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis
2012 sales: $7.285 billion (CHF 6.707 billion)6
2011 sales: $6.523 billion (CHF 6.005 billion)6
% Change: 9% at CER
Q4 2012 sales: $1.856 billion (CHF 1.709 billion), up 7.6% from $1.725 billion (CHF 1.588 billion) in Q4 20116
#4. Advair (fluticasone and salmeterol; sold in some countries as Seretide)
Drug maker: GlaxoSmithKline
Indication(s): Asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema
2012 sales: $7.904 billion (£5.046 billion)7
2011 sales: $7.928 billion (£5.061 billion)7
% Change: 1% at CER
Q4 2012 sales: $2.051 billion (£1.309 billion), down 1% at CER from $2.050 billion (£1.351 billion)7
#3. Enbrel (etanercept)
Drug maker: Amgen and Pfizer8
Indication(s): Moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis
2012 sales: $7.963 billion [$4.236 billion Amgen + $3.737 billion Pfizer]
2011 sales: $7.367 billion [$3.701 billion Amgen + $3.666 billion Pfizer]
% Change: 8%
Q4 2012 sales: $2.118 billion, up 13% from $1.870 billion in Q4 2011
[2012: $1.161 billion Amgen + 0.957 billion Pfizer]
[2011: $0.945 billion Amgen + 0.925 billion Pfizer]
#2. Remicade (infliximab)
Drug maker: Johnson & Johnson and Merck & Co.
Indication(s): Moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate; Crohn's Disease in children 6 years and older, and adults who have not responded well to other medicines; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; chronic, severe, extensive, and/or disabling plaque psoriasis in adults; moderately to severely active ulcerative colitis in children 6 years and older and adults that have not responded well to other medicines
2012 sales: $8.215 billion [$6.139 billion J&J + $2.076 billion Merck & Co.]
2011 sales: $8.159 billion [$5.492 billion J&J + $2.667 billion Merck & Co.]
% Change: 0.7%
Q4 2012 sales: $2.053 billion, up 5.9% from $1.939 billion in Q4 2011
[2012: $1.504 billion J&J + $0.549 billion Merck & Co.]
[2011: $1.428 billion J&J + $0.511 billion Merck & Co.]
#1. Humira (adalimumab)
Drug maker: AbbVie9
Indication(s): Moderate to severe rheumatoid arthritis, moderate to severe chronic plaque psoriasis, moderate to severe Crohn’s disease; moderate to severe ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, moderate to severe polyarticular juvenile idiopathic arthritis
2012 sales: $9.265 billion
2011 sales: $7.932 billion
% Change: 19.3%
Q4 2012 sales: $2.681 billion, up 31.1% from $2.178 billion in Q4 2011
Notes:
1 Also sold by Roche under the brand Neulastim. Roche did not disclose sales figures on Neulastim for 2012 or 2011.
2 Global sales are the sum of sales recorded by Sanofi and Bristol-Myers Squibb (BMS). Sanofi sales figures converted to USD via XE (www.xe.com) on February 11, 2013.
3 Sales figures converted to USD via XE (www.xe.com) on February 11, 2013. Q4 figures not reported for each drug by Roche, but derived by subtracting January-September sales, which are reported by the company in its third-quarter results, from full-year sales. As a result, year-over-year comparisons for Q4 sales are as reported, not at CER.
4 Sales figures converted to USD via XE (www.xe.com) on February 11, 2013. Q4 figures not reported for each drug by Roche, but calculated by subtracting January-September sales, which are reported by the company in its third-quarter results, from full-year sales. As a result, year-over-year comparisons for Q4 sales are as reported, not at CER.
5 Sales figures converted to USD via www.xe.com on Februrary 11, 2013.
6 Sales figures converted to USD via XE (www.xe.com) on February 11, 2013. Q4 figures not reported for each drug by Roche, but derived by subtracting January-September sales, which are reported by the company in its third-quarter results, from full-year sales.
7 Sales figures converted to USD via XE (www.xe.com) on February 11, 2013.
8 Pfizer does not furnish individual sales figures for Enbrel in the U.S. or Canada, but combines them in a category called “Alliance revenues” which also includes sales of Aricept, Exforge, Rebif, and Spiriva.
9 Company spun out January 2, 2013, from Abbott Laboratories, whose portfolio included Humira during 2011 and 2012.